PS2 is an independent prognostic factor for post-relapse survival in primary breast cancer

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 577-582

  Jansen, R L H ^a   Hupperets, P S G J ^a   Arends, J W ^a   Joosten Achjanie, S R ^a   Volovics, A ^b   Hillen, H F P ^a   Schouten, H C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Breast cancer; Post relapse survival; Prognostic factor; PS2

Indexed keywords

PROTEIN PS2;

ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; PLOIDIES; PROGNOSIS; PROTEINS; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEINS;

EID: 0031946880     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Knight WOE III, Livingstone RB, Gregory EG, McGuire WL: Oestrogen-receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37: 4669-4071, 1977.
2. Williams MR, Todd JH, Ellis IO, Dowle CS, Haybitte JL, Elston CW, Nicholson RI, Griffiths K, Blarney RW: Oestrogen-receptors in primary and advanced breast cancer: an eight-year review of 704 cases. Br J Cancer 55: 67-73, 1987.
3. Fisher B, Redmond C, Fisher ER, Caplan R: Relative worth of estrogen and progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Protocol B-06. J Clin Oncol 6: 1076-1087, 1988.
4. Alexeva-Figusch J, van Putten WL, Blankenstein MA, Blonk van der Wijst J, Klijn JG: The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer 61: 758-768, 1988.
5. Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15 (supp): 20-25, 1988.
6. Molino A, Turazza M, Bonetti A, Biondani P, Griso C, Adami L, Corgnati A, Nortilli R, Pollini GP, Modena S: Estrogen and progesterone receptors in breast cancer: correlation with clinical and pathological features and with prognosis. Oncology 49: 82-88, 1992.
7. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG: Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 43: 2985-2990, 1983.
8. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82: 1006-1015, 1990.
9. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Ferno M, Killander D, Olsson H: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045-1053, 1990.
10. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895-7903, 1982.
11. Plaut AG: Trefoil peptides in the defense of the gastrointestinal tract. New Engl J Med 336: 506-507, 1997.
12. Poulsom R: Trefoil peptides. Baillieres Clin Gastroenterol 10: 113-134, 1996.
13. Theisinger B, Welter C, Seitz G, Rio MC, Lathe R, Chambon P, Blin N: Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. Eur J Cancer 27: 770-773, 1991.
14. Seitz G, Theisinger B, Tomasetto C, Rio MC, Chambon P, Blin N, Welter C: Breast cancer associated protein pS2 expression in tumors of the biliary tract. Amer J Gastroenterol 86: 1491-1494, 1991.
15. Welter C, Theisinger B, Seitz G, Tomasetto C, Rio MC, Chambon P, Blin N: Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 66: 187-192, 1992.
16. Welter C, Theisinger B, Rio MC, Seitz G, Schuder G, Blin N: Expression pattern of breast cancer associated protein pS2/BCEI in colorectal tumors. Int J Cancer 56: 52-55, 1994.
17. Hahnel E, Robbins P, Hahnel R: Expression of the pS2 gene in normal breast tissue. Breast Cancer Res Treat 28: 295-297,.1993.
18. Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci 84: 9243-9247, 1987.
19. Foekens JA, Rio MC, Seguin P, van Putten WLJ, Fauque J, Nap M, Klijn JGM, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832-3837, 1990.
20. Predine J, Spyratos F, Prud'homme JF, Andrieu C, Hacene K, Brunet M, Pallud C, Milgrom E: Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors and normal breast tissues. Cancer 69: 2116-2123, 1992.
21. Foekens JA, van Putten WLJ, Portengen H, de Koning HYWCM, Thirion B, Alexieva-Figusch J, Klijn JGM: Prognostic value of pS2 and cathepsin D in 710 primary breast tumors: multivariate analysis. J Clin Oncol 11: 899-908, 1993.
22. Gion M, Mione R, Papagallo R, Gatti C, Nascimben 0, Bari M, Leon AE, Vinante O, Bruscagnin G: PS2 in breast cancer - alternative or complementary tool to steriod receptor status? Evaluation of 446 cases. Br J Cancer 68: 374-379, 1993.
23. Spyratos F, Andrieu MC, Hacene K, Chambon P, Rio MC: PS2 and response to adjuvant hormone therapy in primary breast cancer. Br J Cancer 69: 394-397, 1994.
24. Speiser P, Stolzlechner J, Haiden K, Heinzl H, Jakesz R, Pecherstorfer M, Rosen H, Sevelda P, Zeilliger R: PS2 protein status fails to be an independent prognostic factor in an average breast cancer population. Anticancer Research 14: 2125-2130, 1994.
25. Thor AD, Koerner FC, Edgerton SM, Wood WC, Stacher MA, Schwartz LH: PS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat 21: 111-119, 1992.
26. Cappelletti V, Coradini D, Scanziani E, Benini E, Silvestrini R, Di Fronzo G: Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer 28A: 1315-1318, 1992.
27. Soubeyran 1, Wafflart J, Bonichon F, de Mascarel 1, Trojani M, Durand M, Avril A, Coindre JM: Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 34: 119-128, 1995.
28. Horiguchi J, lino Y, Takei H: Expression of pS2 estrogen-inducible protein in primary breast cancer. Oncology 53: 12-15, 1996.
29. Foekens JA, Portengen H, Look MP, van Putten WLJ, Thirion M, Bontenbal M, Klijn JGM: Relationship of pS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 70: 1217-1223, 1994.
30. Staging for carcinoma of the breast. In: Beahrs O, Henson D, Hutler R, Myers M, eds. Manual for staging of cancer, 3rd ed. Philadelphia, JB Lippincott, 145-150, 1988.
31. Hupperets PSGJ, Wils J, Volovics L, Schouten LJ, Fickers M, Bron H, Schouten H, Jager J, Smeets J, de Jong J, Blijham GH: Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Ann Oncol 4: 295-301, 1993.
32. Hupperets P, Wils J, Volovics L, Schouten LJ, Fickers M, Bron H, Schouten H, Jager J, de Jong J, Blijham GH: Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Update at 7 years follow-up. Ann Oncol 6: 90-91, 1995.
33. Scatchard G. The attraction of proteins from small molecules and ions. Ann NY Ac Sci 51: 660-672, 1949.
34. Henry JA, Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR, May FEB: pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 63: 615-622, 1991.
35. Guesden JL, Ternynck T, Avreamas S: The use of avidin biotin interaction RJ-PS2.ANTI/8 augustus 1997 1 8 in immunoenzymatic techniques. J Histochem Cytochem 27: 1131-1139, 1979.
36. Hedley DW: Flow cytometry using paraffin-embedded tissue: five years on. Cytometry 10: 229-241, 1989.
37. Schutte B, Reynders MMJ, Bosman FTG, Blijham GH: Flow cytometric determination of DNA ploidy level in isolated nuclei from paraffin embedded tissue. Cytometry 6: 26-30, 1986.
38. Vindeløv LL, Christensen U, Nissen NI: A detergent trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 5: 408-419, 1984.
39. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193: 265-275, 1951.
40. Hiddemann W, Schumann J, Andreef M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF, Sandberg AA: Convention of nomenclature for DNA cytometry. Cancer Genet Cytogenet 13: 181-183, 1984.
41. Hupperets PSGJ, Volovics L, Schouten L, Jager J, Schouten HC, Hillen HFP, Blijham GH: The prognostic significance of steroid receptor activity in tumor tissues of patients with primary breast cancer. Am J Clin Oncol, in press, 1997.